BANNER-UNIVERSITY MEDICAL CENTER TUCSON CAMPUS, LLC

Atezolizumab Plus Bevacizumab Shows Superior Outcomes Compared to TACE in Intermediate-Stage Hepatocellular Carcinoma

- Interim analysis from the phase 3b IKF-035/ABC-HCC trial demonstrates that atezolizumab plus bevacizumab achieved a median time to treatment failure of 14.59 months compared to 9.46 months with TACE in intermediate-stage hepatocellular carcinoma patients. - The combination therapy showed a statistically significant 45.5% reduction in risk of treatment failure compared to transarterial chemoembolization (HR, 0.545; P = .0043). - Safety profile was manageable with slightly more adverse events in the immunotherapy combination arm, including higher rates of hypertension, diarrhea, and anorexia compared to TACE. - The multicenter international trial continues enrollment with 231 of 320 planned patients recruited across seven countries as of December 2025.